KraneShares Electric Vehicles and Future Mobility vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $72.00M), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 149.7× KraneShares Electric Vehicles and Future Mobility's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 48 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| KARS | RDY | |
|---|---|---|
Market Cap | $72.00M | $10.78B |
Volume | 31,901 | 2,724,343 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $15.38 |
52-Week Low | $26.72 | $11.38 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $10.68B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →